StocksMedium•29 September 2026•
1 min read
Palvella Therapeutics Completes NDA Submission for QTORIN Rapamycin
Key Facts
1Palvella Therapeutics completed its New Drug Application (NDA) submission for QTORIN rapamycin following positive Phase 3 data.
2The company maintains a robust cash position of $250.6 million to support manufacturing and a targeted commercial launch in H1 2027.
Palvella Therapeutics completed its New Drug Application (NDA) submission for QTORIN rapamycin to treat microcystic lymphatic malformations. Seeking Alpha reported that the submission follows positive Phase 3 clinical data, with the FDA requiring no further efficacy studies for the candidate.
The company maintains a cash position of $250.6 million to fund manufacturing and its targeted commercial launch in the first half of 2027. PVLA closed at $139.83 on September 28, 2026, having reached a session high of $143.55.